Anti-ACHD/ CHRND/ ACHRD monoclonal antibody

Anti-ACHD/ CHRND/ ACHRD antibody for FACS & in-vivo assay

Target products collectionGo to CHRND/CHRND products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0263-Ab-1/ GM-Tg-hg-MP0263-Ab-2Anti-Human CHRND monoclonal antibodyHuman
GM-Tg-rg-MP0263-Ab-1/ GM-Tg-rg-MP0263-Ab-2Anti-Rat CHRND monoclonal antibodyRat
GM-Tg-mg-MP0263-Ab-1/ GM-Tg-mg-MP0263-Ab-2Anti-Mouse CHRND monoclonal antibodyMouse
GM-Tg-cynog-MP0263-Ab-1/ GM-Tg-cynog-MP0263-Ab-2Anti-Cynomolgus/ Rhesus macaque CHRND monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0263-Ab-1/ GM-Tg-felg-MP0263-Ab-2Anti-Feline CHRND monoclonal antibodyFeline
GM-Tg-cang-MP0263-Ab-1/ GM-Tg-cang-MP0263-Ab-2Anti-Canine CHRND monoclonal antibodyCanine
GM-Tg-bovg-MP0263-Ab-1/ GM-Tg-bovg-MP0263-Ab-2Anti-Bovine CHRND monoclonal antibodyBovine
GM-Tg-equg-MP0263-Ab-1/ GM-Tg-equg-MP0263-Ab-2Anti-Equine CHRND monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0263-Ab-1/ GM-Tg-hg-MP0263-Ab-2; GM-Tg-rg-MP0263-Ab-1/ GM-Tg-rg-MP0263-Ab-2;
GM-Tg-mg-MP0263-Ab-1/ GM-Tg-mg-MP0263-Ab-2; GM-Tg-cynog-MP0263-Ab-1/ GM-Tg-cynog-MP0263-Ab-2;
GM-Tg-felg-MP0263-Ab-1/ GM-Tg-felg-MP0263-Ab-2; GM-Tg-cang-MP0263-Ab-1/ GM-Tg-cang-MP0263-Ab-2;
GM-Tg-bovg-MP0263-Ab-1/ GM-Tg-bovg-MP0263-Ab-2; GM-Tg-equg-MP0263-Ab-1/ GM-Tg-equg-MP0263-Ab-2
Products NameAnti-CHRND monoclonal antibody
Formatmab
Target NameCHRND
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CHRND benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ACHD/ CHRND/ ACHRD VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0263
    Target NameCHRND
    Gene ID1144,11447,54240,713354,486162,101098322,281687,100064682
    Gene Symbol and SynonymsAchr-4,ACHRD,Acrd,CHRND,CMS2A,CMS3A,CMS3B,CMS3C,FCCMS,SCCMS
    Uniprot AccessionQ07001,P25110,P04759
    Uniprot Entry NameACHD_HUMAN,ACHD_RAT,ACHD_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000135902
    Target ClassificationN/A

    The target: CHRND, gene name: CHRND, also named as ACHRD, CMS2A, CMS3A, CMS3B, CMS3C, FCCMS, SCCMS. The acetylcholine receptor of muscle has 5 subunits of 4 different types: 2 alpha and 1 each of beta, gamma and delta subunits. After acetylcholine binding, the receptor undergoes an extensive conformation change that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in this gene are a cause of multiple pterygium syndrome lethal type (MUPSL), congenital myasthenic syndrome slow-channel type (SCCMS), and congenital myasthenic syndrome fast-channel type (FCCMS). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.